| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers (NCT05296005) | Ohio State University Comprehensive Cancer Center | 2025-12-31 |
| Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (NCT05836584) | National Cancer Institute (NCI) | 2023-12-06 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (NCT05269381) | Mayo Clinic | 2022-03-31 |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153) | M.D. Anderson Cancer Center | 2022-02-14 |
| Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392) | City of Hope Medical Center | 2022-01-25 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760) | Academic and Community Cancer Research United | 2021-06-16 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937) | National Cancer Institute (NCI) | 2021-04-09 |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors (NCT04771520) | M.D. Anderson Cancer Center | 2021-01-20 |
| Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (NCT04522336) | M.D. Anderson Cancer Center | 2020-09-16 |
| Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04097028) | Roswell Park Cancer Institute | 2019-12-20 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer (NCT04220827) | M.D. Anderson Cancer Center | 2019-12-06 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (NCT03801876) | NRG Oncology | 2019-06-26 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (NCT03604991) | National Cancer Institute (NCI) | 2019-05-03 |
| IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT03918499) | City of Hope Medical Center | 2019-04-19 |
| Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (NCT03776487) | M.D. Anderson Cancer Center | 2019-01-07 |